1. Home
  2. SPFI vs PHAT Comparison

SPFI vs PHAT Comparison

Compare SPFI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo South Plains Financial Inc.

SPFI

South Plains Financial Inc.

N/A

Current Price

$44.25

Market Cap

843.2M

Sector

Finance

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

N/A

Current Price

$7.48

Market Cap

676.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPFI
PHAT
Founded
1941
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
843.2M
676.3M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
SPFI
PHAT
Price
$44.25
$7.48
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$46.00
$19.83
AVG Volume (30 Days)
94.5K
1.0M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
1.68%
N/A
EPS Growth
17.81
42.72
EPS
1.82
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$22.65
$93.04
Revenue Next Year
$9.40
$58.91
P/E Ratio
$24.22
N/A
Revenue Growth
N/A
216.93
52 Week Low
$35.34
$7.31
52 Week High
$46.94
$18.31

Technical Indicators

Market Signals
Indicator
SPFI
PHAT
Relative Strength Index (RSI) 51.59 33.83
Support Level $44.05 N/A
Resistance Level $45.56 $9.74
Average True Range (ATR) 0.79 0.45
MACD -0.06 -0.12
Stochastic Oscillator 47.91 9.51

Price Performance

Historical Comparison
SPFI
PHAT

About SPFI South Plains Financial Inc.

South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: